112 related articles for article (PubMed ID: 2702975)
21. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
Mross K; Maessen P; van der Vijgh WJ; Gall H; Boven E; Pinedo HM
J Clin Oncol; 1988 Mar; 6(3):517-26. PubMed ID: 3162516
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic herb-drug interactions between Aidi injection and doxorubicin in rats with diethylnitrosamine-induced hepatocellular carcinoma.
Lu Y; Pan J; Zhu X; Zhang S; Liu C; Sun J; Li Y; Chen S; Huang J; Cao C; Wang Y; Li Y; Liu T
BMC Pharmacol Toxicol; 2021 Sep; 22(1):48. PubMed ID: 34488896
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of two different delivery regimens of doxorubicin in isolated hyperthermic limb perfusion.
Pfeiffer T; Krause U; Thome U; Skorzek M; Scheulen ME
Eur J Surg Oncol; 1995 Oct; 21(5):551-4. PubMed ID: 7589605
[TBL] [Abstract][Full Text] [Related]
25. Methyl-beta-cyclodextrin and doxorubicin pharmacokinetics and tissue concentrations following bolus injection of these drugs alone or together in the rabbit.
Grosse PY; Bressolle F; Rouanet P; Joulia JM; Pinguet F
Int J Pharm; 1999 Apr; 180(2):215-23. PubMed ID: 10370192
[TBL] [Abstract][Full Text] [Related]
26. Investigation of hepatobiliary disposition of doxorubicin following intrahepatic delivery of different dosage forms.
Lilienberg E; Ebeling Barbier C; Nyman R; Hedeland M; Bondesson U; Axén N; Lennernäs H
Mol Pharm; 2014 Jan; 11(1):131-44. PubMed ID: 24171458
[TBL] [Abstract][Full Text] [Related]
27. Doxorubicin area under the curve is an important predictor of neutropenia in dogs with naturally occurring cancers.
Wittenburg LA; Weishaar K; Ramirez D; Gustafson DL
Vet Comp Oncol; 2019 Jun; 17(2):147-154. PubMed ID: 30638304
[TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study.
Freyer G; Tranchand B; Ligneau B; Ardiet C; Souquet PJ; Court-Fortune I; Riou R; Rebattu P; Boissel JP; Trillet-Lenoir V; Girard P
Br J Clin Pharmacol; 2000 Oct; 50(4):315-24. PubMed ID: 11012554
[TBL] [Abstract][Full Text] [Related]
29. The effects of lipiodol and cyclosporin A on the hepatobiliary disposition of doxorubicin in pigs.
Dubbelboer IR; Lilienberg E; Hedeland M; Bondesson U; Piquette-Miller M; Sjögren E; Lennernäs H
Mol Pharm; 2014 Apr; 11(4):1301-13. PubMed ID: 24558959
[TBL] [Abstract][Full Text] [Related]
30. Epirubicin. Clinical pharmacology and dose-effect relationship.
Robert J
Drugs; 1993; 45 Suppl 2():20-30. PubMed ID: 7693418
[TBL] [Abstract][Full Text] [Related]
31. Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer.
DiPaola RS; Rinehart J; Nemunaitis J; Ebbinghaus S; Rubin E; Capanna T; Ciardella M; Doyle-Lindrud S; Goodwin S; Fontaine M; Adams N; Williams A; Schwartz M; Winchell G; Wickersham K; Deutsch P; Yao SL
J Clin Oncol; 2002 Apr; 20(7):1874-9. PubMed ID: 11919247
[TBL] [Abstract][Full Text] [Related]
32. A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients.
Robert J; Monnier A; Poutignat N; Hérait P
Cancer Chemother Pharmacol; 1991; 29(1):75-9. PubMed ID: 1742853
[TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of 4'-O-tetrahydropyranyladriamycin given on a weekly schedule in patients with advanced breast cancer.
Mader RM; Zilg H; Schlappack O; Steger GG; Baur M; Greifenberg B; Heberle U; Dittrich C
Cancer Chemother Pharmacol; 1995; 37(1-2):91-6. PubMed ID: 7497603
[TBL] [Abstract][Full Text] [Related]
35. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
Gabizon A; Catane R; Uziely B; Kaufman B; Safra T; Cohen R; Martin F; Huang A; Barenholz Y
Cancer Res; 1994 Feb; 54(4):987-92. PubMed ID: 8313389
[TBL] [Abstract][Full Text] [Related]
36. Analysis and pharmacokinetics of N-l-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice.
de Jong J; Klein I; Bast A; van der Vijgh WJ
Cancer Chemother Pharmacol; 1992; 31(2):156-60. PubMed ID: 1451235
[TBL] [Abstract][Full Text] [Related]
37. Quantification of DOX bioavailability in biological samples of mice by sensitive and precise HPLC assay.
Zhang C; Wu Y; Dong Y; Xu H; Zhao L
Pharm Biol; 2016; 54(1):55-61. PubMed ID: 25880143
[TBL] [Abstract][Full Text] [Related]
38. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.
Lyass O; Uziely B; Ben-Yosef R; Tzemach D; Heshing NI; Lotem M; Brufman G; Gabizon A
Cancer; 2000 Sep; 89(5):1037-47. PubMed ID: 10964334
[TBL] [Abstract][Full Text] [Related]
39. Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients.
Yu LR; Cao Z; Makhoul I; Daniels JR; Klimberg S; Wei JY; Bai JP; Li J; Lathrop JT; Beger RD; Todorova VK
Exp Biol Med (Maywood); 2018 Feb; 243(3):248-255. PubMed ID: 29224368
[TBL] [Abstract][Full Text] [Related]
40. Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin.
Conley BA; Egorin MJ; Whitacre MY; Carter DC; Zuhowski EG; Van Echo DA
Cancer Chemother Pharmacol; 1993; 33(2):107-12. PubMed ID: 8261569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
